

Lecture Series CCC-N Cancer Club

Prof. Dr. med. Günter Schneider (UMG), PD Dr. Matthias Wirth (UMG),
and PD Dr. Anna Saborowski (MHH)

(previous co-organizers: Gudrun Göhring (MHH), Anke Bergmann (MHH))

List of previous talks in the series:

07.02.2022

Dr. med. Raphael Koch, Department of Hematology and Medical Oncology (UMG)

Exploring functional vulnerabilities in T-cell lymphoma and beyond

07.03.2022

Prof. Dr. med. Klaus Pantel, Institute of Tumor Biology (UKE Hamburg)

Liquid Biopsy: From Discovery to Clinical Implementation

25.04.2022

PD Dr. med. Thomas Wirth, Department of Gastroenterology, Hepatology and Endocrinology (MHH)

Immunotherapy of GI Cancers. From Checkpoint Inhibition to Personalized Vaccines

16.05.2022

PD Dr. Dr. Lena Conradi, Department of General, Visceral and Pediatric Surgery (UMG)

Vessel Co-option versus Angiogenesis in Colorectal Cancer Liver Metastases

20.06.2022

Dr. Sonja Woermann, Ahmed Center for Pancreatic Cancer Research, The University of Texas MD
Anderson Cancer Center, US

The Role of APOBEC3A in Pancreatic Cancer

05.09.2022

Prof. Dr. med. Diana Steinmann, Clinic for Radiotherapy and Special Oncology (MHH)

Complementary Medicine in Oncology - What Else Can Patients Do?

10.10.2022

Dr. Arnab Nayak, Institute for Molecular and Cell Physiology (MHH)

Cachexia and the SUMO pathway – a new paradigm of muscle wasting disorders

24.10.2022

Dr. Benedikt Westphalen, CCC Munich (LMU)

Access to innovative care - scaling precision oncology

07.11.2022

Dr. Asha Balakrishnan, Department of Gastroenterology, Hepatology and Endocrinology (MHH)

Interactions between cellular processes, metabolic pathways, and miRNAs in HCC

05.12.2022

Dr. Shiv Singh, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology
(UMG)

Cell-extrinsic and –intrinsic mechanisms in pancreatic cancer heterogeneity and therapy response

12.12.2022

Prof. Dr. med. Jens Siveke, WTZ Essen
Translational approaches in pancreatic cancer

09.01.2023

Dr. Benedikt Nilges, ESBC Leuven
Studying tumor heterogeneity and microenvironments with single cell spatial transcriptomics

06.02.2023

Dr. Sara Haag (TRAIN Niedersachsen) & **PD Dr. Sara Nußbeck** (UMG)
Lower Saxony Unified Biobank – An Infrastructure to Support Translational Research

20.02.2023

Alexander Berg & Dr. Liat Hayardeny-Brueck (both UMG Knowledge and Technology Transfer)
From Bench to Bedside – How the UMG Accelerates Drug Development

01.03.2023

Prof. Dr. Maximilian Reichert, TU München
Functionalizing patient-derived organoids to model intra-tumoral heterogeneity in pancreatic cancer

17.04.2023

Prof. Dr. Marc Schmidt-Supprian, LMU München
Balancing B-Cell Responses between Protective Immunity, Autoimmunity and Lymphomagenesis

15.05.2023

Prof. Dr. Ulrich Keller, Charité Berlin
The activated MYC-SUMO axis in cancer: mechanisms and targeting

26.06.2023

Prof. Dr. Alexander Kleger, Ulm
Epithelial genotypes determine niche reprogramming during pancreatic carcinogenesis

04.09.2023

Dr. Christian Braun, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich
Targeting imbalanced transcription programs in cancer

08.11.2023

Alan Coy, Roche Pharma
Digitalization in Oncology

04.12.2023

Dr. Siegfried Hauch, Qiagen GmbH
Matched Analysis of Liquid Biopsy Components in ER+ Her2-Breast Cancer – Is there a Master Analyte?

18.12.2023

Prof. Dr. Michael Altenbuchinger, UMG
High-dimensional statistical approaches for (multi-)omics and spatial transcriptomics data: applications to cancer research

15.01.2024

Prof. Dr. Svenja Meierjohann, Universität Würzburg
Stress adaptation in melanoma: the role of NRF2

20.02.2024

Prof. Dr. Hana Algül, Technische Universität München
Pancreatic Carcinoma - What's Standard, What's Next?

04.03.2024

Prof. Dr. Uta-Maria Bauer, Philipps Universität Marburg
PRMTs - important players in human malignancies

11.03.2024

Prof. Dr. Martin-Leo Hansmann, Goethe Universität Frankfurt
Strategic lymph node diagnostics in 3D and movement-4D

08.04.2024

Prof. Dr. Elias Arnér, Karolinska Institutet Stockholm
Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets

29.04.2024

Prof. Dr Christian Reinhardt, West German Cancer Center Essen
Mouse models of aggressive lymphoma as preclinical avatars to dissect biology and for the development of therapeutic strategies

05.08.2024

Prof. Dr. Wolfgang Sippl, Martin-Luther-Universität Halle-Wittenberg
Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets

02.09.2024

Prof. Dr. Florian Heidel, Medizinische Hochschule Hannover
Effectors of malignant JAK-signaling

11.11.2024

Prof. Dr. Elmar Wolf, Christian-Albrechts-Universität zu Kiel
Targeting the oncogenic function of MYC in PDAC

02.12.2024

Prof. Dr. Martin Sos, Ludwig-Maximilians-Universität München
Exploiting molecular dependencies in lung cancer

15.01.2025

Dr. Dan Lu, Harvard Medical School
Dynamic combinatorial p53 post-translational modifications regulate cell fate

10.02.2025

Prof. Dr. Gunnar Schotta, Ludwig Maximilians Universität München
Silent Invaders: Unraveling the Regulation of Endogenous Retroviruses

10.03.2025

Prof. Dr. Stefan Hüttelmaier, Martin-Luther-Universität Halle-Wittenberg
Targeting RNS Binding Proteins (RBPs) and microRNAs in Cancer Therapy